By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
GlycoMimetics, Inc. (GLYC) To Receive $20 Million Payment From Pfizer Following Initiation Of Phase III Trial With Rivipansel 6/24/2015 11:38:36 AM
GlycoMimetics, Inc. (GLYC) To Present At The Jefferies and Co. 2015 Healthcare Conference 5/28/2015 11:24:21 AM
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015 12:42:26 PM
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015 11:27:23 AM
FDA Grants Orphan Drug Designation To GlycoMimetics, Inc. (GLYC)’ GMI-1271 For Treatment Of Acute Myleogenous Leukemia (AML) 5/14/2015 10:59:57 AM
GlycoMimetics, Inc. (GLYC) Reports First Quarter 2015 Results 5/6/2015 11:52:25 AM
GlycoMimetics, Inc. (GLYC) Provides Update On Pfizer (PFE)’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015 4/7/2015 9:48:11 AM
GlycoMimetics, Inc. (GLYC) To Present First Preclinical Data On E-Selectin-CXCR4 Dual Antagonist For Cancer Indications At American Association for Cancer Research Annual Meeting 2015 3/19/2015 11:38:26 AM
GlycoMimetics, Inc. (GLYC) Reports Fourth Quarter And Year-End 2014 Results 3/17/2015 11:47:41 AM
GlycoMimetics, Inc. (GLYC) Announces Publication Of Phase 2 Data For Rivipansel In Sickle Cell Disease 3/3/2015 10:23:23 AM
123456789
//-->